Post-COVID-19 cognitive impairments (literature review)

Abstract

Post-COVID-19 condition (PCC) is a condition that occurs in patients with a history of SARS-CoV-2 infection 3 months after the onset of COVID-19 with symptoms that last at least 2 months and are not explained by any other diseases. PCC affects from 17 % to 28 % of patients and includes a wide range of clinical manifestations, including cognitive dysfunction. Cognitive dysfunctions can be manifested by a wide range of symptoms, such as memory impairment, attention deficit, executive dysfunction, and reduced information processing speed. Risk factors for developing PCC, with or without cognitive impairment, include late adulthood, pre-existing medical conditions, and severity of acute illness. The underlying mechanisms remain unclear, but suspected factors include neuroinflammation, hypoxia, vascular damage and latent reactivation of the virus, this does not exclude the possibility of direct viral central nervous system invasion. The analysis of retrospective cohort studies showed that the risk of cognitive deficits, dementia, psychotic disorders and seizures remained elevated even 2 years after the infection of SARS-CoV-2. It is interesting to note that there were no differences in the risks of neurological and psychiatric outcomes between infections caused by Omicron (B.1.1.529) or Delta (B.1.617.2) variants. Recent researches show that cognitive deficits after infection of SARS-CoV-2 persist for two years after the infection and were the greatest in individuals with more severe SARS-CoV-2 infection [2].  COVID-19 can impair the function of the interoceptive network of the brain selectively, while exteroceptive brain processing remains undamaged [3].

Keywords

Post-COVID-19 condition / cognitive impairment / post-COVID disorders

References

[1] Möller M., Borg K., Janson C. et al. Cognitive dysfunction in post-COVID-19 condition: Mechanisms, management, and rehabilitation. J Intern Med. 2023; 27. DOI: 10.1111/joim.13720.

[2] Cheetham N.J., Penfold R., Giunchiglia V. et al. The effects of COVID-19 on cognitive performance in a community-based cohort: a COVID symptom study biobank prospective cohort study. E Clinical Medicine. 2023; 62: 102086. DOI: 10.1016/j.eclinm.2023.102086.

[3] Ceban F., Ling S., Lui L.M.W. et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav Immun. 2022; 101: 93–135. DOI: 10.1016/j.bbi.2021.12.020.

[4] Han Q., Zheng B., Daines L., Sheikh A. Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of One-Year Follow-Up Studies on Post-COVID Symptoms. Pathogens. 2022; 11 (2): 269. DOI: 10.3390/patho-gens11020269.

[5] Aziz R., Siles N., Kelley M. et al. Clinical characteristics of Long COVID patients presenting to a dedicated academic post-COVID-19 clinic in Central Texas. Sci Rep. 2023; 13 (1): 21971. DOI: 10.1038/s41598-023-48502-w.

[6] Khieukhajee J., Rojana-Udomsart A., Srisarakorn P. et al. Cognitive Impairment and Risk Factors in Post-COVID-19 Hospitalized Patients. Dement Geriatr Cogn Dis Extra. 2023; 13 (1): 18–27. DOI: 10.1159/000531743.

[7] Vasile M.C., Vasile C.I., Arbune A.A. et al. Cognitive Dysfunction in Hospitalized Patient with Moderate-to-Severe COVID-19: A 1-Year Prospective Observational Study. J Multidiscip Healthc. 2023; 16: 3367–3378. DOI: 10.2147/JMDH.S432969.

[8] Taquet M., Sillett R., Zhu L. et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry. 2022; 9 (10): 815–827. DOI: 10.1016/S2215-0366(22)00260-7.

[9] Kamp S.M., Buntić N., Amtmann J. et al. Reduced concentration performance and heartbeatevoked potential in individuals with a history of a SARS-CoV-2 infection. Neurosci Lett. 2023; 814: 137466. DOI: 10.1016/j.neulet.2023.137466.

[10] Gouraud C., Thoreux P., Ouazana-Vedrines C. et al. Patients with persistent symptoms after COVID-19 attending a multidisciplinary evaluation: Characteristics, medical conclusions, and satisfaction. J Psychosom Res. 2023; 174: 111475. DOI:10.1016/j.jpsychores.2023.111475.

[11] Jayasekera M.M.P.T., De Silva N.L., Edirisinghe E.M.D.T. et al. A prospective cohort study on post COVID syndrome from a tertiary care centre in Sri Lanka. Sci Rep. 2023; 13 (1): 15569. DOI: 10.1038/s41598-023-42350-4.

[12] Kozik V., Reuken P., Utech I. et al. Characterization of neurocognitive deficits in patients with post-COVID-19 syndrome: persistence, patients' complaints, and clinical predictors. Front Psychol. 2023; 14: 1233144. DOI: 10.3389/fpsyg.2023.1233144.

[13] Buonsenso D., Munblit D., De Rose C., Sinatti D., Ricchiuto A., Carfi A., Valentini P. Preliminary evidence on long COVID in children. Acta Paediatr. 2021; 110 (7): 2208–2211. DOI: 10.1111/apa.15870. Epub 2021 Apr 18. PMID: 33835507; PMCID: PMC8251440.

[14] Almeria M., Cejudo J.C., Sotoca J., Deus J., Krupinski J. Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment. Brain Behav Immun Health. 2020; 9: 100163. DOI: 10.1016/j.bbih.2020.100163. Epub 2020 Oct 22. PMID: 33111132; PMCID: PMC7581383.

[15] Morello R., Mariani F., Mastrantoni L., De Rose C., Zampino G., Munblit D., Sig-frid L., Valentini P., Buonsenso D. Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study. E Clinical Medicine. 2023

[16] Troitskaya L.A., Plotnikova I.A., Avakyan G.G., Erokhina V.A., Badalyan O.L., Muraveva A.V., Zelentsova V.L., Khodko O.K., Safarova S.T., Shirokova E.I., Rusina E.A., Sanina N.P., Terentev K.V., Rachin A.P. Neuropsychological evaluation of cognitive disorders in children after COVID-19. Eur J Transl Myol. 2022; 32 (3): 10685. DOI: 10.4081/ejtm.2022.10685. PMID: 35838578; PMCID: PMC9580531.

[17] Коротаева К.С., Фурман Е.Г., Сумливая О.Н. Интегральные показатели лейкоцитарной формулы у детей с коронавирусной инфекцией COVID-19. Пермский медицинский журнал 2022; 39 (1): 27–34 / Korotaeva K.S., Furman E.G., Sumlivaya O.N. Integral'nye pokazateli lejkocitarnoj formuly u detej s koronavirusnoj infekciej COVID-19. Permskij medicinskij zhurnal 2022; 39 (1): 27–34 (in Russian).

[18] Shariff S., Uwishema O., Mizero J. et al. Long-term cognitive dysfunction after the COVID-19 pandemic: a narrative review. Ann Med Surg (Lond). 2023; 85 (11): 5504–5510. DOI: 10.1097/MS9.0000000000001265.

[19] Yulug B., Ayyıldız B., Ayyıldız S. et al. In-fection with COVID-19 is no longer a public emergency: But what about degenerative dementia? J Med Virol. 2023; 95 (9): e29072. DOI: 10.1002/jmv.29072.

[20] Marjenberg Z., Leng S., Tascini C. et al. Risk of long COVID main symptoms after SARS-CoV-2 infection: a systematic review and meta-analysis. Sci Rep. 2023; 13 (1): 15332. DOI: 10.1038/s41598-023-42321-9.

RIGHTS & PERMISSIONS

Eco-Vector